Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures
Ontario and Chicago, Illinois--(Newsfile Corp. - May 10, 2023) - Medexus Pharmaceuticals (TSX: MDP) (TSX: MDP.DB) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its 6% unsecured convertible debentures due 2023 (TSX: MDP.DB). Under the NCIB, Medexus may purchase for cancellation
2023-05-10 5:30 PM EDT
Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma
Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan® (aminolevulinic acid HCl) oral solution, compared to conventional white light surgery, in US patients with high-grade glioma. The data were presented at ISPOR 2023, the annual meeting of the Professional Society for Health Economics and Outcomes Research (formerly known as the International Society for...
2023-05-09 6:21 PM EDT